Clinical trial
Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de…
NCT00464399 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00464399 |
|---|---|
| Title | Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients |
| Official title | A Pilot Study to Evaluate Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | De Novo Renal Transplantation |
| Intervention type | Drug |
| Interventions | everolimus |
| Enrollment | 20 |
| Start date | Sep 1, 2006 |
| Primary completion | Dec 1, 2012 |
| First posted | Apr 23, 2007 |
| Last update posted | Nov 16, 2016 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: